comparemela.com

Latest Breaking News On - Harbour biomed - Page 1 : comparemela.com

CTLA-4 Inhibitors Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism Of Action, Route Of Administration, And Comp...

Fierce Pharma Asia—AstraZeneca eyes China's innovation, plots Singapore ADC plant; FDA rejects Hengrui's PD-1 drug

Fierce Pharma Asia—AstraZeneca eyes China's innovation, plots Singapore ADC plant; FDA rejects Hengrui's PD-1 drug
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Germany
Japan
Florida
United-states
China
Singapore
Japanese
German
Chinese
British
Pascal-soriot

AstraZeneca pays $19M for Nona's preclinical cancer antibodies

AstraZeneca pays $19M for Nona's preclinical cancer antibodies
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

China
Massachusetts
United-states
Chinese
Jingsong-wang
Nona-biosciences
Astrazeneca
Pfizer
Big-pharma
Harbour-biomed
Big-pharmas

Harbour BioMed Reports Full Year 2023 Financial Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ Harbour BioMed , a global biopharmaceutical company committed to the discovery, development and.

Australia
Netherlands
Shanghai
China
Hong-kong
Cambridge
Cambridgeshire
United-kingdom
Suzhou
Jiangsu
Boston
Massachusetts

Mice Model Market Worth $2.2 billion | MarketsandMarkets

Mice Model Market Worth $2.2 billion | MarketsandMarkets
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

China
Northbrook
Queensland
Australia
Lesen
Aquitaine
France
Chicago
Illinois
United-states
Japan
India
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.